美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Apollomics

0.0136

-0.0006-4.23%

成交量：1.50萬

成交額：206.64

市值：1.50萬

市盈率：- -

高：0.0142

開：0.0142

低：0.0136

收：0.0142

52周最高：0.0489

52周最低：0.0047

股本：110.33萬

流通股本：110.33萬

量比：3.32

換手率：1.36%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

聽證會取消後，Apollomics 宣佈繼續於 The Nasdaq Stock Market 維持其上市地位

Apollomics, Inc. 公司營運持續性最新消息

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/APLMW"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"APLMW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APLMW\",,,,,undefined,":{"symbol":"APLMW","market":"US","secType":"STK","nameCN":"Apollomics","latestPrice":0.0136,"timestamp":1770755971853,"preClose":0.0142,"halted":0,"volume":15016,"delay":0,"changeRate":-0.042253521126760674,"floatShares":1103333,"shares":1103333,"eps":0,"marketStatus":"交易中","change":-0.0006,"latestTime":"02-10 15:48:24 EST","open":0.0142,"high":0.0142,"low":0.0136,"amount":206.637743736,"amplitude":0.042254,"askPrice":0.0138,"askSize":6215,"bidPrice":0.0132,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0142,"volumeRatio":3.323258},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APLMW\",,,,,undefined,":{"symbol":"APLMW","floatShares":1103333,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.323258,"shares":1103333,"dividePrice":0,"high":0.0142,"amplitude":0.042254,"preClose":0.0142,"low":0.0136,"week52Low":0.0047,"pbRate":"--","week52High":0.0489,"institutionHeld":0,"latestPrice":0.0136,"committee":-0.108337,"eps":0,"divideRate":0,"volume":15016,"delay":0,"ttmEps":0,"open":0.0142,"prevYearClose":0.0111,"prevWeekClose":0.0142,"prevMonthClose":0.0147,"prevQuarterClose":0.0111,"fiveDayClose":0.0143,"twentyDayClose":0.0149,"sixtyDayClose":0.0193},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APLMW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APLMW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APLMW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APLMW\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576726193","title":"聽證會取消後，Apollomics 宣佈繼續於 The Nasdaq Stock Market 維持其上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2576726193","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576726193?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 00:28","pubTimestamp":1760632080,"startTime":"0","endTime":"0","summary":"公司今天宣布于 2025 年 10 月 14 日收到 Nasdaq 的来函，通知 Apollomics 上市资格人员已判定该公司符合于 Nasdaq 继续上市的要求。因此，Nasdaq 已取消其上诉听证会，而公司的证券仍可在 The Nasdaq Stock Market 上市及继续交易。Apollomics 的主导项目为 vebreltinib 。前瞻性陈述仅代表截至 Apollomics 发布之日时的状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3168186/0/zh-hant/%E8%81%BD%E8%AD%89%E6%9C%83%E5%8F%96%E6%B6%88%E5%BE%8C-Apollomics-%E5%AE%A3%E4%BD%88%E7%B9%BC%E7%BA%8C%E6%96%BC-The-Nasdaq-Stock-Market-%E7%B6%AD%E6%8C%81%E5%85%B6%E4%B8%8A%E5%B8%82%E5%9C%B0%E4%BD%8D.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","TQQQ","NVIW.SI",".IXIC","NQmain","QLD","PSQ","SQQQ","QID","TSYW.SI","USAW.SI","MNQmain","APLMW"],"gpt_icon":1},{"id":"2575732369","title":"Apollomics, Inc. 公司營運持續性最新消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2575732369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575732369?lang=zh_tw&edition=fundamental","pubTime":"2025-10-16 00:19","pubTimestamp":1760545140,"startTime":"0","endTime":"0","summary":"由于 APL-101 已处于临床试验后期阶段，且过往患者病情发展良好，因此 APL-101 作为 Apollomics 的核心投资项目，必须持续推进并进一步研发。Apollomics 目前拥有 12 名全职员工。Apollomics 预期至 2025 年 10 月 31 日总员工总数将达 15 人。Apollomics 认为现行员工人数足以维持临床试验与营运。Apollomics 还计划削减中国大陆员工人数，并将员工人数重新分配至美国及台湾地区。前瞻性陈述仅代表截至 Apollomics 发布之日时的状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/15/3167357/0/zh-hant/Apollomics-Inc-%E5%85%AC%E5%8F%B8%E7%87%9F%E9%81%8B%E6%8C%81%E7%BA%8C%E6%80%A7%E6%9C%80%E6%96%B0%E6%B6%88%E6%81%AF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLMW"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/APLMW\",params:#limit:6,delay:false,,,undefined,":[]}}